GlassScriptPhysician profile
Sandeep Singh Gill
NPI 1730122631
$13,157.40
in general payments reported to CMS, 2019-2025
41 companies · $1,012 in 2025
The $1,012 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $505 · 2021: $122 · 2022: $1,431 · 2023: $392 · 2024: $9,695 · 2025: $1,012.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,820 · Food and Beverage: $2,013 · Travel and Lodging: $1,169 · Education: $96.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,820.00 |
| Food and Beverage | $2,013.31 |
| Travel and Lodging | $1,169.04 |
| Education | $96.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $9,194.13 | 2023-2024 | Ultomiris |
| Rigel Pharmaceuticals, INC. | $1,274.53 | 2021-2022 | |
| Incyte Corporation | $375.26 | 2019-2025 | Jakafi |
| Celgene Corporation | $322.73 | 2022-2025 | Reblozyl, Opdualag |
| Astellas Pharma US INC | $205.61 | 2019 | |
| Novartis Pharmaceuticals Corporation | $137.62 | 2019-2025 | |
| Glaxosmithkline, LLC. | $128.61 | 2023-2025 | Jemperli, Zejula, Ojjaara |
| Teleflex LLC | $123.39 | 2025 | Barrigel |
| Genzyme Corporation | $114.35 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $105.77 | 2024-2025 | Keytruda, Lynparza, Welireg |
| Lilly USA, LLC | $96.97 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $85.90 | 2023-2025 | Lynparza, Calquence |
| E.R. Squibb & Sons, L.L.C. | $80.76 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $64.34 | 2025 | |
| Pharmaessentia USA Corporation | $62.77 | 2022-2025 | Besremi |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $58.75 | 2019 | |
| Abbvie INC. | $52.93 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $48.75 | 2024-2025 | Libtayo |
| Sirtex Medical INC | $46.88 | 2023 | Sir-Spheres Microspheres |
| Eisai INC. | $46.36 | 2023-2025 | |
| Daiichi Sankyo INC. | $41.36 | 2021-2025 | Enhertu |
| Beigene USA, INC. | $37.55 | 2024-2025 | Tevimbra |
| Sobi, INC | $35.68 | 2025 | |
| Medtronic, INC. | $29.42 | 2024 | Osteocool Rf Ablation System |
| Tempus Ai, INC | $29.20 | 2024 | |
| Amgen INC. | $27.79 | 2023 | Nplate, Vectibix |
| Blueprint Medicines Corporation | $26.81 | 2025 | Ayvakit |
| Kite Pharma, INC. | $26.60 | 2025 | Yescarta |
| Aveo Pharmaceuticals, INC. | $25.96 | 2025 | |
| Servier Pharmaceuticals LLC | $24.86 | 2024 | |
| Gilead Sciences, INC. | $23.93 | 2025 | Trodelvy |
| Harmony Biosciences LLC | $23.50 | 2025 | |
| Janssen Biotech, INC. | $23.43 | 2025 | Talvey, Tecvayli |
| Array Biopharma INC | $23.03 | 2024 | Xalkori, Lorbrena, Braftovi |
| Geron Corporation | $22.47 | 2024 | Rytelo |
| Pfizer INC. | $20.85 | 2024 | |
| Kyowa Kirin, INC. | $20.73 | 2024 | Poteligeo |
| Seagen INC. | $20.45 | 2023 | Padcev |
| Recordati_rare_diseases_inc. | $16.97 | 2025 | Sylvant |
| Karyopharm Therapeutics INC. | $15.45 | 2025 | Xpovio |
| Agios Pharmaceuticals, INC. | $14.95 | 2024 | Pyrukynd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandeep Gill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.